We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

14 hedge funds and large institutions have $1.19M invested in Evoke Pharma in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

8% more funds holding

Funds holding: 13 → 14 (+1)

0.03% more ownership

Funds ownership: 0% → 0.03% (+0.03%)

17% less capital invested

Capital invested by funds: $1.43M → $1.19M (-$244K)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SOMRS
State of Michigan Retirement System
Michigan
+$72K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$32.4K
3
VKH
Virtu KCG Holdings
New York
+$31.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$30K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$20.5K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$271K
2
SM
Sabby Management
Florida
-$144K
3
CPIG
Chicago Partners Investment Group
Illinois
-$2K
4
UBS Group
UBS Group
Switzerland
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$447K +$13.7K +53 +4%
SOMRS
2
State of Michigan Retirement System
Michigan
$364K +$72K +278 +29%
California Public Employees Retirement System
3
California Public Employees Retirement System
California
$74K – – –
BFA
4
BlackRock Fund Advisors
California
$63K +$8.03K +31 +17%
Commonwealth Equity Services
5
Commonwealth Equity Services
Massachusetts
$61K +$32.4K +125 +149%
VKH
6
Virtu KCG Holdings
New York
$35K +$31.3K +121 New
Citadel Advisors
7
Citadel Advisors
Florida
$34K +$30K +116 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$32K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$23K +$20.5K +79 New
AIM
10
Acrospire Investment Management
Illinois
$21K +$18.7K +72 New
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$20K +$18.1K +70 New
Bank of America
12
Bank of America
North Carolina
$4K – – –
Morgan Stanley
13
Morgan Stanley
New York
$4K +$3.11K +12 +400%
BIM
14
BlackRock Investment Management
Delaware
$3K – – –
Renaissance Technologies
15
Renaissance Technologies
New York
– -$271K -833 Closed
SM
16
Sabby Management
Florida
– -$144K -443 Closed
CPIG
17
Chicago Partners Investment Group
Illinois
– -$2K -7 Closed
UBS Group
18
UBS Group
Switzerland
– -$1K -2 Closed

EVOK Hedge Fund Activity: Q4 2016 in Review

14 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2016, worth a combined $1.19M — down 17% from $1.43M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EVOK positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.

The largest buyer was State of Michigan Retirement System, adding an estimated $72K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $271K sold.

  • 14 institutional investors held Evoke Pharma (EVOK) as of Q4 2016, up from 13 in Q3 2016.
  • Funds reported $1.19M of Evoke Pharma stock for Q4 2016, down 17% quarter-over-quarter.
  • 5 funds opened new Evoke Pharma positions in Q4 2016 and 4 closed out, a net change of +1 holder.
  • The largest Evoke Pharma buyer in Q4 2016 was State of Michigan Retirement System, an estimated $72K added.
  • The largest Evoke Pharma seller in Q4 2016 was Renaissance Technologies, an estimated $271K sold.

Based on aggregated 13F filings for Q4 2016.